Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2022 | The current state of the art in ALL and how novel agents are impacting the field

Nicholas Short • 29 Sep 2022
SOHO 2022
Acute Lymphoblastic Leukemia Leukemia Antibodies Blinatumomab Dasatinib Hyper-CVAD Imatinib Inotuzumab ozogamicin Ponatinib

Nicholas Short, MD, University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into the current state of the art in acute lymphoblastic leukemia (ALL), commenting on how the use of tyrosine kinase inhibitors (TKIs) and antibody therapies in the frontline setting have transformed the field. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Nicholas Short

2:50
The impact of induction therapy on post-transplant outcomes in AML
Nicholas Short • 6 Sep 2023
2:20
Pevonedistat, azacitidine and venetoclax triplet therapy for AML, MDS and CMML
Nicholas Short • 6 Sep 2023
2:30
The importance of MRD-guided therapy in ALL
Nicholas Short • 6 Sep 2023
2:40
The role of PCR and NGS-based MRD in Ph+ ALL
Nicholas Short • 6 Sep 2023

Related Videos

2:24
Manipulating the gut microbiome to improve outcomes of alloSCT for hematological malignancies
Florent Malard • 11 Apr 2024
2:05
Investigating mutation order in AML using single-cell sequencing
Ravindra Majeti • 8 Apr 2024
3:12
An epitope editing approach to enable the use of targeted immunotherapy in AML
Gabriele Casirati • 9 Apr 2024
0:59
Developing LSC-targeting agents in AML: progress and current therapeutic capacity
Ravindra Majeti • 8 Apr 2024
The content of VJHemOnc is intended for healthcare professionals